Merck & Co is one of the investors set to exit antibody drug developer Visterra after Otsuka Pharmaceutical agreed to buy the company for $430m.
Otsuka Pharmaceutical, the pharmaceutical subsidiary of healthcare and nutrition group Otsuka Holdings, agreed yesterday to acquire US-based antibody developer Visterra for $430m, allowing drug producer Merck & Co to exit.
Visterra is developing precision antibody-based therapeutics designed to modulate disease targets not currently treatable by other antibody-based drugs.
The candidates are based on the company’s Hierotope platform, and its pipeline includes prospective treatments for kidney diseases including IgA nephropathy, where the immunoglobulin A antibody gets lodged in the kidneys. as…
